I. Gardner

639 total citations
17 papers, 510 citations indexed

About

I. Gardner is a scholar working on Molecular Biology, Oncology and Computational Theory and Mathematics. According to data from OpenAlex, I. Gardner has authored 17 papers receiving a total of 510 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Computational Theory and Mathematics. Recurrent topics in I. Gardner's work include Computational Drug Discovery Methods (4 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). I. Gardner is often cited by papers focused on Computational Drug Discovery Methods (4 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). I. Gardner collaborates with scholars based in United Kingdom, United States and Germany. I. Gardner's co-authors include Masoud Jamei, Lisa M. Almond, Jane R. Kenny, Amin Rostami‐Hodjegan, Susan Wong, Zoe Golder, Stéphane Berghmans, Paul Butler, W. Alderton and Frances M. Richards and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Drug Metabolism and Disposition and Toxicology Letters.

In The Last Decade

I. Gardner

13 papers receiving 498 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
I. Gardner United Kingdom 10 195 133 103 67 60 17 510
David C. McMillan United States 19 137 0.7× 157 1.2× 75 0.7× 44 0.7× 126 2.1× 28 732
Masato Kitajima Japan 15 122 0.6× 261 2.0× 113 1.1× 69 1.0× 63 1.1× 20 607
P E Sanders United States 12 121 0.6× 214 1.6× 78 0.8× 35 0.5× 23 0.4× 20 526
Anna-Karin Sohlenius-Sternbeck Sweden 12 282 1.4× 171 1.3× 212 2.1× 38 0.6× 46 0.8× 22 594
Hozeifa Mohamed Hassan China 18 200 1.0× 339 2.5× 144 1.4× 50 0.7× 34 0.6× 36 780
Tomáš Smutný Czechia 17 219 1.1× 224 1.7× 162 1.6× 31 0.5× 50 0.8× 33 710
Frank W. Lee United States 13 218 1.1× 173 1.3× 184 1.8× 74 1.1× 79 1.3× 21 698
Sang Seop Lee South Korea 20 326 1.7× 237 1.8× 327 3.2× 65 1.0× 121 2.0× 40 859
Brigitte Gerin Belgium 7 215 1.1× 226 1.7× 132 1.3× 32 0.5× 127 2.1× 11 761
Appavu Chandrasekaran United States 15 92 0.5× 178 1.3× 82 0.8× 54 0.8× 22 0.4× 43 595

Countries citing papers authored by I. Gardner

Since Specialization
Citations

This map shows the geographic impact of I. Gardner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Gardner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Gardner more than expected).

Fields of papers citing papers by I. Gardner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Gardner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Gardner. The network helps show where I. Gardner may publish in the future.

Co-authorship network of co-authors of I. Gardner

This figure shows the co-authorship network connecting the top 25 collaborators of I. Gardner. A scholar is included among the top collaborators of I. Gardner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Gardner. I. Gardner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Stader, Felix, et al.. (2025). Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics. 52(4). 35–35.
2.
Moore, Holly, Aki T. Heikkinen, Sibylle Neuhoff, et al.. (2025). Investigating Sulfotransferase Mediated Drug Interactions of Ethinylestradiol using a Physiologically Based Pharmacokinetic Model. The AAPS Journal. 28(1). 13–13.
3.
Graepel, Rabea, Bas ter Braak, Sylvia E. Escher, et al.. (2019). Paradigm shift in safety assessment using new approach methods: The EU-ToxRisk strategy. Current Opinion in Toxicology. 15. 33–39. 7 indexed citations
4.
5.
6.
Almond, Lisa M., Sophie Mukadam, I. Gardner, et al.. (2016). Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model. Drug Metabolism and Disposition. 44(6). 821–832. 91 indexed citations
7.
Fisher, Ciarán, Oliver Hatley, I. Gardner, & Masoud Jamei. (2016). A multi-compartment liver model for the prediction of toxicokinetics. Toxicology Letters. 258. S121–S121.
8.
Gaohua, Lu, Ben G. Small, Lisa M. Almond, et al.. (2015). Development of a Multicompartment Permeability‐Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs. CPT Pharmacometrics & Systems Pharmacology. 4(10). 605–613. 64 indexed citations
9.
Gardner, I., et al.. (2014). Incorporating Target Shedding Into a Minimal PBPK–TMDD Model for Monoclonal Antibodies. CPT Pharmacometrics & Systems Pharmacology. 3(1). 1–13. 27 indexed citations
10.
Almond, Lisa M., Amin Rostami‐Hodjegan, I. Gardner, et al.. (2013). A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease–Drug Interactions: Suppression of CYP3A by IL-6. Clinical Pharmacology & Therapeutics. 94(2). 260–268. 86 indexed citations
11.
Alderton, W., Stéphane Berghmans, Paul Butler, et al.. (2010). Accumulation and metabolism of drugs and CYP probe substrates in zebrafish larvae. Xenobiotica. 40(8). 547–557. 94 indexed citations
12.
Walker, Don K., John D. Davis, Christopher Houle, I. Gardner, & Rob Webster. (2009). Species differences in the multiple-dose pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) UK-453,061 in animals and man: implications for safety considerations. Xenobiotica. 39(7). 534–543. 10 indexed citations
13.
Jones, Richard, et al.. (2008). Strategies to preventN-acetyltransferase-mediated metabolism in a series of piperazine-containing pyrazalopyrimidine compounds. Xenobiotica. 38(9). 1219–1239. 5 indexed citations
14.
15.
Berghmans, Stéphane, Teresa P. Barros, Zoe Golder, et al.. (2008). Zebrafish: The future of in vivo safety pharmacology screening. Journal of Pharmacological and Toxicological Methods. 58(2). 177–178. 1 indexed citations
16.
Gardner, I., et al.. (2000). Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: implications for fluperlapine-induced agranulocytosis.. PubMed. 28(3). 255–63. 20 indexed citations
17.
Gardner, I., Don K. Walker, M. S. Lennard, Dennis A. Smith, & Georgianne Tucker. (1995). Comparison of the disposition of two novel combined thromboxane synthase inhibitors/thromboxane A2receptor antagonists in the isolated perfused rat liver. Xenobiotica. 25(2). 185–197. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David C. McMillan Breakdown of academic impact, for papers by Masato Kitajima Breakdown of academic impact, for papers by P E Sanders Breakdown of academic impact, for papers by Anna-Karin Sohlenius-Sternbeck Breakdown of academic impact, for papers by Hozeifa Mohamed Hassan Breakdown of academic impact, for papers by Tomáš Smutný Breakdown of academic impact, for papers by Frank W. Lee Breakdown of academic impact, for papers by Sang Seop Lee Breakdown of academic impact, for papers by Brigitte Gerin Breakdown of academic impact, for papers by Appavu Chandrasekaran
Rankless by CCL
2026